Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,996,424
  • Shares Outstanding, K 224,526
  • Annual Sales, $ 3,696 M
  • Annual Income, $ 597,600 K
  • 60-Month Beta 0.65
  • Price/Sales 3.27
  • Price/Cash Flow 22.12
  • Price/Book 2.33
Trade INCY with:

Options Overview Details

View History
  • Implied Volatility 33.36% ( -2.39%)
  • Historical Volatility 16.19%
  • IV Percentile 90%
  • IV Rank 55.31%
  • IV High 46.79% on 02/12/24
  • IV Low 16.74% on 05/18/23
  • Put/Call Vol Ratio 14.27
  • Today's Volume 504
  • Volume Avg (30-Day) 649
  • Put/Call OI Ratio 1.39
  • Today's Open Interest 18,403
  • Open Int (30-Day) 15,512

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.68
  • Number of Estimates 6
  • High Estimate 0.87
  • Low Estimate 0.50
  • Prior Year 0.18
  • Growth Rate Est. (year over year) +277.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.15 +0.13%
on 04/16/24
59.03 -9.84%
on 03/21/24
-5.15 (-8.82%)
since 03/15/24
3-Month
53.15 +0.13%
on 04/16/24
62.19 -14.42%
on 01/23/24
-8.12 (-13.24%)
since 01/16/24
52-Week
50.27 +5.87%
on 10/31/23
75.74 -29.73%
on 05/01/23
-21.28 (-28.56%)
since 04/14/23

Most Recent Stories

More News
SEC Explores New Territory in Insider Trading Case Against Ex-Biotech Exec

In a groundbreaking trial in San Francisco, the U.S. Securities and Exchange Commission (SEC) is testing the boundaries of insider trading laws. The case against former biotech executive Matthew Panuwat...

PFE : 25.69 (-0.85%)
INCY : 53.22 (-0.39%)
Stock Indexes Climb to Record Highs on a Tech Fueled Rally

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.44%. Stock indexes this morning...

$SPX : 5,051.41 (-0.21%)
SPY : 503.53 (-0.18%)
$DOWI : 37,798.97 (+0.17%)
DIA : 377.98 (+0.18%)
$IUXX : 17,713.66 (+0.04%)
QQQ : 431.10 (+0.01%)
ZNM24 : 107-190 (-0.07%)
LYV : 92.21 (-7.58%)
NVDA : 874.15 (+1.64%)
CVNA : 70.64 (+1.16%)
SQ : 73.14 (-0.49%)
FLNC : 16.05 (+2.03%)
Stocks Slump as Hot U.S. CPI Report Dashes Fed Rate Cut Hopes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -1.37%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 5,051.41 (-0.21%)
SPY : 503.53 (-0.18%)
$DOWI : 37,798.97 (+0.17%)
DIA : 377.98 (+0.18%)
$IUXX : 17,713.66 (+0.04%)
QQQ : 431.10 (+0.01%)
MCO : 370.73 (-0.75%)
BIIB : 195.15 (-0.84%)
ZTS : 153.02 (+2.17%)
MAR : 245.62 (-1.12%)
VFC : 12.57 (+3.46%)
ANET : 262.76 (-0.17%)
Incyte: Q4 Earnings Snapshot

Incyte: Q4 Earnings Snapshot

INCY : 53.22 (-0.39%)
Pancreatic Cancer Treatments Poised for Major Advances in 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END

ONCY : 1.0800 (+1.89%)
ONC.TO : 1.47 (+0.68%)
INCY : 53.22 (-0.39%)
TNGX : 7.35 (+0.41%)
BMY : 48.26 (-0.52%)
RYZB : 62.49 (+0.02%)
Innovative Strategies in the Fight Against Pancreatic Cancer: A 2023 Recap

USA News Group – One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among...

PFE : 25.69 (-0.85%)
ONCY : 1.0800 (+1.89%)
ONC.TO : 1.47 (+0.68%)
INCY : 53.22 (-0.39%)
TNGX : 7.35 (+0.41%)
BMY : 48.26 (-0.52%)
RYZB : 62.49 (+0.02%)
Incyte: Q3 Earnings Snapshot

Incyte: Q3 Earnings Snapshot

INCY : 53.22 (-0.39%)
The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm

VANCOUVER – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial...

AAPL : 169.38 (-1.92%)
NYT : 42.19 (-0.05%)
ONCY : 1.0800 (+1.89%)
ONC.TO : 1.47 (+0.68%)
MACK : 14.68 (unch)
INCY : 53.22 (-0.39%)
MRTX : 58.70 (-0.17%)
BNTX : 86.34 (-1.76%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 370.68 (-1.48%)
ABBV : 162.54 (+0.54%)
ABCL : 4.05 (-3.11%)
ALNY : 146.72 (-0.66%)
AMGN : 265.64 (+0.05%)
ANAB : 21.34 (+0.33%)
AZN : 68.26 (-0.68%)
BMY : 48.26 (-0.52%)
INCY : 53.22 (-0.39%)
REGN : 894.14 (-0.49%)
VIE : 53.01 (unch)
Pancreatic Cancer Battle Boosted by $200M VC Firm

/PRNewswire/ -- USA News Group - A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent...

ONC.TO : 1.47 (+0.68%)
ONCY : 1.0800 (+1.89%)
MACK : 14.68 (unch)
INCY : 53.22 (-0.39%)
MRTX : 58.70 (-0.17%)
BNTX : 86.34 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 54.76
2nd Resistance Point 54.43
1st Resistance Point 53.82
Last Price 53.22
1st Support Level 52.88
2nd Support Level 52.55
3rd Support Level 51.94

See More

52-Week High 75.74
Fibonacci 61.8% 66.01
Fibonacci 50% 63.00
Fibonacci 38.2% 60.00
Last Price 53.22
52-Week Low 50.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar